{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.5","upperLimit":"61.1","value":"41.4"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"41.2","upperLimit":"63.4","value":"52.4"},{"groupId":"OG003","lowerLimit":"42.2","upperLimit":"70.7","value":"56.9"},{"groupId":"OG004","lowerLimit":"28.1","upperLimit":"63.6","value":"45.5"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.7","upperLimit":"73.6","value":"55.2"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"59.3","upperLimit":"79.7","value":"70.2"},{"groupId":"OG003","lowerLimit":"60.4","upperLimit":"85.7","value":"74.5"},{"groupId":"OG004","lowerLimit":"45.1","upperLimit":"79.6","value":"63.6"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.3","upperLimit":"79.3","value":"62.1"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"67.0","upperLimit":"85.8","value":"77.4"},{"groupId":"OG003","lowerLimit":"69.1","upperLimit":"91.6","value":"82.4"},{"groupId":"OG004","lowerLimit":"51.3","upperLimit":"84.4","value":"69.7"}]}],"title":"36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.3","upperLimit":"79.3","value":"62.1"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"72.3","upperLimit":"89.6","value":"82.1"},{"groupId":"OG003","lowerLimit":"76.1","upperLimit":"95.6","value":"88.2"},{"groupId":"OG004","lowerLimit":"54.5","upperLimit":"86.7","value":"72.7"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.7","upperLimit":"82.1","value":"65.5"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"73.6","upperLimit":"90.6","value":"83.3"},{"groupId":"OG003","lowerLimit":"78.6","upperLimit":"96.7","value":"90.2"},{"groupId":"OG004","lowerLimit":"54.5","upperLimit":"86.7","value":"72.7"}]}],"title":"60 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.7","upperLimit":"82.1","value":"65.5"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"75.0","upperLimit":"91.5","value":"84.5"},{"groupId":"OG003","lowerLimit":"78.6","upperLimit":"96.7","value":"90.2"},{"groupId":"OG004","lowerLimit":"57.7","upperLimit":"88.9","value":"75.8"}]}],"title":"72 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.7","upperLimit":"82.1","value":"65.5"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"75.0","upperLimit":"91.5","value":"84.5"},{"groupId":"OG003","lowerLimit":"78.6","upperLimit":"96.7","value":"90.2"},{"groupId":"OG004","lowerLimit":"57.7","upperLimit":"88.9","value":"75.8"}]}],"title":"84 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.2","upperLimit":"84.7","value":"69.0"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"},{"groupId":"OG002","lowerLimit":"75.0","upperLimit":"91.5","value":"84.5"},{"groupId":"OG003","lowerLimit":"78.6","upperLimit":"96.7","value":"90.2"},{"groupId":"OG004","lowerLimit":"57.7","upperLimit":"88.9","value":"75.8"}]}],"title":"90 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"84"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time qPCR. MMR for participants with the p210 BCR-ABL transcript variant is defined according to the recommendations of Hughes et al. as a ratio BCR-ABL/ABL \\<= 10-3 or 0.1% on the international scale proposed by the authors. The standardized baseline, as established in the IRIS trial, is taken to represent 100% on the international scale and a 3-log reduction in ratio (BCR-ABL transcripts/ABL or BCR) from the standardized baseline (MMR) is fixed at 0.1%. In this study, ABL or other housekeeping gene, will be used as the control-gene. For a participant with the p190 BCR-ABL transcript variant, on-study assessments will be compared to the participant's individual baseline BCR-ABL/ABL ratio and a reduction to \\< 0.1% or a 3-log reduction from baseline will be considered an MMR. The percentage of treated participants with MMR is reported by arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"90 months","title":"Major Molecular Response (MMR) Rate up to 7.5 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}